Professor David Price
Chair of Primary Care Respiratory Med
- 51cg
-
- Email Address
- d.price@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437237
- School/Department
- School of Medicine, Medical Sciences and Nutrition
- Publications
-
Page 6 of 20 Results 251 to 300 of 964
Sociodemographic and clinical characteristics of patients with asthma who were prescribed ≥3 SABA canisters/year in the SABINA International study
European Respiratory Society (ERS) International Congress., 3397Contributions to Journals: Abstracts- [ONLINE] DOI:
Mortality Analyses on Systemic Corticosteroid Use: a Long-term Observational Study
BTS Winter Meeting 2021, pp. A7-A8Contributions to Journals: Abstracts- [ONLINE] DOI:
- [OPEN ACCESS]
- [ONLINE]
Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
17th Annual Deutscher Allergiekongress (DAK) 2022, pp. 212Contributions to Journals: Abstracts- [ONLINE] DOI:
- [OPEN ACCESS]
Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
Eastern Pulmonary Conference 2022Contributions to Conferences: Abstracts- [ONLINE]
A pragmatic primary practice approach to using specific IgE in allergy testing in asthma diagnosis, management, and referral
Journal of Asthma and Allergy, vol. 2022, no. 15, pp. 1069—1080Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
Correspondence to Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2LEN consensus
Allergy, vol. 77, no. 8, pp. 2571-2573Contributions to Journals: Letters- [ONLINE] DOI:
- [ONLINE]
COPD Population in US Primary Care: Data From the Optimum Patient Care DARTNet Research Database and the Advancing the Patient Experience in COPD Registry
Annals of Family Medicine, vol. 20, no. 4, pp. 319-327Contributions to Journals: Articles- [ONLINE] DOI:
Oral corticosteroid (OCS) risk predictor for Type II Diabetes in asthma
European Respiratory Society (ERS) International Congress.Contributions to Conferences: Abstracts- [OPEN ACCESS]
A Response to: Letter to the Editor Regarding “Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab”
Advances in Therapy, vol. 39, no. 8, pp. 3862-3865Contributions to Journals: Letters- [ONLINE] DOI:
- [OPEN ACCESS]
- [ONLINE]
Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
Aspen Allergy Conference – 40th MeetingContributions to Conferences: AbstractsPersistent OCS reduction regardless of starting OCS dose in patients with severe, OCS-dependent asthma treated with dupilumab: LIBERTY ASTHMA TRAVERSE study
15º Congreso ALAT 2022Contributions to Conferences: AbstractsCharacterisation of the Australian adult population living with asthma: Severe exacerbation frequency, long-term OCS use and adverse effects.
Pragmatic and Observational Research, vol. 2022, pp. 43-58Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
Healthcare resource utilisation associated with intermittent oral corticosteroid use in asthma
EAACI HYBRID CONGRESS 2022Contributions to Conferences: Abstracts- [ONLINE]
Biologics in severe asthma: the role of real-world evidence from registries
European Respiratory Review, vol. 31, no. 164, 210278Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
- [ONLINE]
Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
2022 AANP National ConferenceContributions to Conferences: PostersLet’s improve COPD prognosis: a practical tool for primary care providers to identify the frequency and follow-up of COPD lung attacks
Dutch Lung Congress 2022Contributions to Conferences: AbstractsReply to: Cause or consequence?
European Respiratory Journal, vol. 59, no. 6, 2200103Contributions to Journals: Comments and Debates- [ONLINE] DOI:
- [OPEN ACCESS]
- [OPEN ACCESS]
Reducing asthma attacks in children using exhaled nitric oxide (RAACENO) as a biomarker to inform treatment strategy: a multicentre, parallel, randomised, controlled, phase 3 trial
The Lancet. Respiratory medicine, vol. 10, no. 6, pp. 584-592Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
- [ONLINE]
Reducción persistente de corticosteroides orales independientemente de la dosis basal, en pacientes con asma córtico-dependiente tratados con dupilumab: Estudio Liberty Asthma-Traverse
55 Congreso Separ, pp. 75Contributions to Journals: Abstracts- [ONLINE]
- [ONLINE]
- [ONLINE]
Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
The 35th annual
Eastern Allergy Conference, pp. S9Contributions to Conferences: Abstracts- [ONLINE]
- [ONLINE]
Quality Standard Position Statements for Health System Policy Changes in Diagnosis and Management of COPD: A Global Perspective
Advances in Therapy, vol. 39, pp. 2302–2322Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
Treatment guided by fractional exhaled nitric oxide in addition to standard care in 6- to 15-year-olds with asthma: the RAACENO RCT
Efficacy and Mechanism Evaluation, vol. 9, no. 4Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers
npj Primary Care Respiratory Medicine, vol. 32, no. 1, 18Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
- [ONLINE]
Evaluation of critical inhalation technique errors in patients with COPD on Dry Powder Inhaler maintenance therapy based on their association with health status: findings from the PIFotal study.
IPCRG 2022Contributions to Conferences: Abstracts- [ONLINE]
Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study
European Respiratory Journal, vol. 59, no. 5Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
Suboptimal peak inspiratory flow and inhalation technique errors are associated with higher COPD-relateD healthcare costs: results from the PIFotal COPD study
IPCRG 2022Contributions to Conferences: Abstracts- [ONLINE]
The burden of intermittent oral corticosteroid use in asthma
IPCRG 2022Contributions to Conferences: Abstracts- [ONLINE]
Adverse Outcomes Post-initiation of Systemic Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease: A Long-term Observational UK-based Study
ATS 2022Contributions to Journals: Abstracts- [ONLINE] DOI:
Clinical Remission in Severe Asthma: A Pooled Post hoc Analysis of the Patient Journey with Benralizumab
Advances in Therapy, vol. 39, no. 5, pp. 2065–2084Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
Impact of initiating biologics in patients with severe asthma and on long-term oral corticosteroids or rescue steroids (GLITTER)
ATS 2022, D102Contributions to Journals: Abstracts- [ONLINE] DOI:
Persistent Reductions in OCS Use in Patients with Severe, OCS-Dependent Asthma Treated with Dupilumab: LIBERTY ASTHMA TRAVERSE Study
ATS 2022, A2365Contributions to Journals: Abstracts- [ONLINE] DOI:
Predicting Pneumonia events in COPD patients using medical records
ATS 2022Contributions to Journals: Abstracts- [ONLINE] DOI:
Prevalence of comorbidities in adults with severe asthma: results from the International Severe Asthma Registry (ISAR)
ATS 2022Contributions to Journals: Abstracts- [ONLINE] DOI:
Prototype ORACLE Score Validation in NOVELTY: Predicted versus Observed Asthma Exacerbation Rates
ATS 2022, A486Contributions to Journals: Abstracts- [ONLINE] DOI:
Relationships Between Symptoms and Lung Function in Asthma and/or Chronic Obstructive Pulmonary Disease in the NOVELTY study
ATS 2022, A4013Contributions to Journals: Abstracts- [ONLINE] DOI:
Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma
The Journal of Allergy and Clinical Immunology: In Practice, vol. 10, no. 5Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
- [OPEN ACCESS]
Variation in demographic and clinical characteristics of Patients with COPD receiving care in U.S. primary care: data from the Advancing the Patient EXperience (APEX) in COPD registry
Pragmatic and Observational Research, vol. 2022, no. 13, pp. 17-31Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial. (BICS)
Trials, vol. 23, no. 1, 307Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
Asthma exacerbation and steroid burden in Australian primary care
The Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science 2022, pp. 194Contributions to Journals: Abstracts- [ONLINE] DOI:
- [OPEN ACCESS]
No difference in pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus long-acting bronchodilators
TSANZSRS 2022, pp. 28-29Contributions to Journals: Abstracts- [ONLINE] DOI:
- [OPEN ACCESS]
A pooled analysis of mortality in patients with COPD receiving dual bronchodilation with and without additional inhaled corticosteroid
International journal of chronic obstructive pulmonary disease , vol. 2022, no. 17, pp. 545—558Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
Lower pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone
The Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science 2022, pp. 81Contributions to Journals: Abstracts- [ONLINE] DOI:
- [OPEN ACCESS]
CONQUEST: a quality improvement program for defining and optimizing standards of care for modifiable high-risk COPD patients
Patient Related Outcome Measures, vol. 2022, no. 13, pp. 53-68Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
Interclass difference in pneumonia risk in COPD patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasone
International journal of chronic obstructive pulmonary disease , vol. 2022, no. 17, pp. 355—370Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
Ethnic differences in severe asthma clinical care and outcomes: an analysis of United Kingdom primary and specialist care
The Journal of Allergy and Clinical Immunology: In Practice, vol. 10, no. 2, pp. 495-505Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to move forward
American Journal of Respiratory and Critical Care Medicine, vol. 205, no. 3, pp. 275-287Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
Fast Decliner Phenotype of Chronic Obstructive Pulmonary Disease (COPD): Applying Machine Learning for Predicting Lung Function Loss
BMJ Open Respiratory Research, vol. 8, no. 1, e000980Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise
npj Primary Care Respiratory Medicine, vol. 32, no. 1, pp. 6Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]
- [ONLINE]
Real world biologic use and switch patterns in severe asthma: data from the International Severe Asthma Registry and the US CHRONICLE Study
Journal of Asthma and Allergy, vol. 15, pp. 63-78Contributions to Journals: Articles- [OPEN ACCESS]
Measuring peak inspiratory flow in patients with chronic obstructive pulmonary disease
International journal of chronic obstructive pulmonary disease , vol. 17, pp. 79-92Contributions to Journals: Articles- [ONLINE] DOI:
- [OPEN ACCESS]